Abstract:MicroRNAs (miRs) are master regulators of post-transcriptional gene expression, and they are often dysregulated in individuals suffering from diabetes. We investigated the roles of miR-101-3p and miR-204-5p, both of which negatively regulate insulin secretion and cell survival and are highly expressed in pancreatic β cells, in the context of type 1 diabetes (T1D) pathogenesis. Using quantitative real time PCR, we evaluated serum levels of miR-101-3p and miR-204-5p in four groups, including recent-onset T1D patients (T1D group; n = 50), individuals with normal glucose levels expressing one islet autoantibody (Ab) (single Ab group; n = 26) or multiple autoantibodies (multiple Ab group; n = 12), and healthy controls (control group; n = 43). An in silico analysis was performed to identify potential target genes of these miRNAs and to delineate enriched pathways. The relative expression of serum miR-101-3p was approximately three times higher in the multiple Ab and T1D groups than that in the single Ab and control groups (p < 0.0001). When considering all groups together, miR-101-3p expression was positively correlated with the level of islet autoantibodies GADA (r = 0.267; p = 0.0027) and IA-2A (r = 0.291; p = 0.001), and the expression of the miRNA was not correlated with levels of ZnT8A (r = 0.125; p = 0.183). miR-101-3p expression did not correlate with HbA1c (r = 0.178; p = 0.052) or glucose levels (r = 0.177; p = 0.051). No significant differences were observed in miR-204-5p expression among the analyzed groups. Computational analysis of the miR-101-3p target gene pathways indicated a potential activation of the HGF/c-Met, Ephrin receptor, and STAT3 signaling pathways. Our study demonstrated that the circulating levels of miR-101-3p are higher in T1D patients and in individuals with normal glucose levels, testing positive for multiple autoantibodies, indicating that miR-101-3p precedes loss of glucose homeostasis. The pathogenic role of miR-101-3p in T1D may involve multiple molecular pathways.

miRNA-Mediated Immune Regulation in Islet Autoimmunity and Type 1 Diabetes

miRNA Regulation of T Cells in Islet Autoimmunity and Type 1 Diabetes

MicroRNAs in Type 1 Diabetes: Complex Interregulation of the Immune System, β Cell Function and Viral Infections

Mirnas: Novel Regulators of Autoimmunity-Mediated Pancreatic Β-Cell Destruction in Type 1 Diabetes

MicroRNA Networks in Pancreatic Islet Cells: Normal Function and Type 2 Diabetes

Decreased Mir-146 Expression in Peripheral Blood Mononuclear Cells is Correlated with Ongoing Islet Autoimmunity in Type 1 Diabetes Patients

Increased Expression of Circulating microRNA 101-3p in Type 1 Diabetes Patients: New Insights Into miRNA-Regulated Pathophysiological Pathways for Type 1 Diabetes

Micro-RNA Implications in Type-1 Diabetes Mellitus: A Review of Literature

Innate Immunity in Type 1 Diabetes

Immune Regulation in T1D and T2D: Prospective Role of Foxp3+ Treg Cells in Disease Pathogenesis and Treatment

Insights into the development of insulin-producing cells: Precursors correlated involvement of microRNA panels

The role of islet autoantigen-specific T cells in the onset and treatment of type 1 diabetes mellitus

New Developments in T Cell Immunometabolism and Therapeutic Implications for Type 1 Diabetes

MiR-30a Targets IL-1α and Regulates Islet Functions As an Inflammation Buffer and Response Factor.

Rebalancing the Immune System to Treat Type 1 Diabetes

Mir-101A and Mir-30B Contribute to Inflammatory Cytokine-Mediated Β-Cell Dysfunction

Regulatory T Cells and Type 1 Diabetes

Type-1 interferon induced cross-regulation of IL-10 function: a novel mechanism in type 1 diabetes development

The immunology of type 1 diabetes

LRH-1/NR5A2 Activation Rewires Immunometabolism Blunting Inflammatory Immune Cell Progression in Individuals with Type 1 Diabetes and Enhances Human Islet Function in Mice

Regulatory Roles of MicroRNAs in Diabetes